PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24486524-8	2014	CONCLUSIONS: (a) ERalpha(+) breast cancer cells dysfunctional for TP53 which proliferate irrespective of low estrogen and chemical MEK inhibition are likely to increase metabolic consumption becoming increasingly susceptible to 3-BrPA; (b) targeting the pyruvate pathway may improve response to endocrine therapy in ERalpha(+) breast cancer with p53 dysfunction.	Pyruvic Acid	254-262	tumor protein p53	Homo sapiens	66-70